Related Experiment Video
Updated: Aug 6, 2026
04:14
Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis (NASH) Resolution
Published on: April 16, 2019
Glucosyl hesperidin benefits in primary biliary cholangitis: a multicenter, open-label, randomized controlled study
Kei Moriya1,2, Kiyoshi Asada2,3, Naoki Ozu3
1Department of Gastroenterology, Nara Prefecture General Medical Center.
Clinical and Translational Gastroenterology
|July 16, 2026
Summary
Glucosyl hesperidin (G-Hes) safely improved liver enzymes in primary biliary cholangitis (PBC) patients. High-dose G-Hes significantly reduced gamma-glutamyl transferase (GGT), indicating a potential new therapy for PBC.
Area of Science:
- Hepatology
- Biochemistry
- Clinical Trials
Background:
- Primary biliary cholangitis (PBC) incidence is rising, with limited treatment options for disease progression.
- Understanding PBC pathophysiology and exploring novel therapeutic targets are crucial.
Purpose of the Study:
- To evaluate the therapeutic effects of glucosyl hesperidin (G-Hes) on PBC.
- To investigate G-Hes's impact on hepatobiliary enzymes and the NRF2/KEAP1 pathway.
Main Methods:
- A 24-week randomized controlled trial involving 71 PBC patients on maintenance therapy.
- Patients received G-Hes at 500 mg or 1,000 mg daily.
- Serum levels of liver enzymes, lipids, and heme oxygenase 1 were assessed.
Main Results:
- High-dose G-Hes (1,000 mg) significantly decreased gamma-glutamyl transferase (GGT) by 6.2%.
- Standard-dose G-Hes (500 mg) led to a significant decrease in bilirubin.
- No significant changes in transaminases were observed; G-Hes was well-tolerated.
Conclusions:
- Glucosyl hesperidin (G-Hes) offers additional therapeutic benefits when added to existing PBC treatments.
- G-Hes demonstrates a safe profile and potential for improving PBC management.